ROCHE HOLDING AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.01 EUR | +2.35% |
|
+7.25% | -5.74% |
| Jun. 07 | Roche: efficacy of Evrysdi in spinal muscular atrophy | CF |
| Jun. 07 | Roche's Five-year Data Confirms Efficacy, Safety of Evrysdi Drug for Spinal Muscular Atrophy in Children | MT |
| Sales 2024 * | 60.39B 67.33B 62.35B | Sales 2025 * | 63.83B 71.17B 65.9B | Capitalization | 196B 219B 203B |
|---|---|---|---|---|---|
| Net income 2024 * | 13.27B 14.79B 13.7B | Net income 2025 * | 14.76B 16.46B 15.24B | EV / Sales 2024 * | 3.48 x |
| Net Debt 2024 * | 13.77B 15.35B 14.22B | Net Debt 2025 * | 7.88B 8.79B 8.14B | EV / Sales 2025 * | 3.2 x |
| P/E ratio 2024 * |
14.3
x | P/E ratio 2025 * |
12.9
x | Employees | - |
| Yield 2024 * |
4.04% | Yield 2025 * |
4.15% | Free-Float | 88.91% |
More Fundamentals
* Assessed data
More news
Latest transcript on Roche Holding AG
More recommendations
More press releases
More news
| 1 week | +7.25% | ||
| Current month | +7.25% | ||
| 1 month | +11.38% | ||
| 3 months | +1.61% | ||
| 6 months | -5.17% | ||
| Current year | -5.74% |
1 week
29.19
31.01
1 month
27.7331.01
3 years
27.1049.33
5 years
27.1049.33
10 years
22.0049.33
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 49 | 02-12-31 | |
Severin Schwan
CHM | Chairman | 57 | 07-12-31 |
Alan Hippe
DFI | Director of Finance/CFO | 57 | 11-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bernard Poussot
BRD | Director/Board Member | 72 | 15-03-02 |
| Director/Board Member | 59 | - | |
| Director/Board Member | 66 | 95-12-31 |
| Date | Price | Change |
|---|---|---|
| 24-06-07 | 31.01 | +2.35% |
| 24-06-06 | 30.3 | +0.64% |
| 24-06-05 | 30.11 | +1.07% |
| 24-06-04 | 29.79 | -0.83% |
| 24-06-03 | 30.04 | +3.88% |
Delayed Quote Börse Stuttgart, June 07, 2024 at 10:11 am EDT
More quotes
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
Pharmaceuticals
Calendar
2024-06-11
- Goldman Sachs Global Healthcare Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
242.6
CHF
Average target price
277.5
CHF
Spread / Average Target
+14.40%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +45.82% | 765B | |
| +40.95% | 632B | |
| -6.16% | 354B | |
| +19.86% | 331B | |
| +9.32% | 299B | |
| +18.45% | 248B | |
| +11.88% | 216B | |
| +5.90% | 164B | |
| -0.73% | 162B |
- Stock Market
- Equities
- ROG Stock
- RHO6 Stock
